Your browser doesn't support javascript.
loading
The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials.
Hayes, Aimee R; Chan, David L H; Chan, Bryan A; Pavlakis, Nick.
Afiliación
  • Hayes AR; Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, UK.
  • Chan DLH; The University of Sydney, Camperdown, NSW, Australia.
  • Chan BA; The University of Sydney, Camperdown, NSW, Australia.
  • Pavlakis N; Neuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal North Shore Hospital, St Leonards, NSW, Australia.
J Neuroendocrinol ; 33(9): e13015, 2021 Sep.
Article en En | MEDLINE | ID: mdl-34397130
The quality and reporting of neuroendocrine tumour (NET) clinical trials has previously been found to be heterogeneous impairing trial interpretability. We aimed to perform an updated review of the quality of phase II/III clinical trials in NET to assess if trial design and reporting have improved since 2011. We performed a PubMed search for phase II/III trials evaluating systemic anticancer therapies or liver-directed therapies published between 2011 and 2018. Data collected comprised administrative data, study population characteristics, endpoints, reporting and statistical design parameters, and results. Sixty studies were included (5218 patients): 50 phase II and 10 phase III trials. Study populations were heterogeneous: 52% of trials allowed tumours from various primary sites, 28% allowed both well- and poorly-differentiated tumour morphology or did not specify, and 57% did not report proliferative indices and/or tumour grade in ≥80% of the study population. Only 36% of trials mandated radiological disease progression on participant enrolment using a validated measure. Statistical design and primary endpoint were clearly defined in 67% and 88% of trials, respectively. Toxicity (88%), radiological response rate (85%) and progression-free survival/time to progression (82%) were well reported in a majority of trials, but health-related quality of life was included in the minority. Of the randomised trials (n = 11), study populations were more homogeneous and study design was more often clearly defined; however, only 45% mandated radiological progression at baseline as measured per Response Evaluation Criteria In Solid Tumours, and reporting of health-related quality of life (55%) remained suboptimal. The design and reporting of NET clinical trials, predominantly of single-arm phase II trials, remains suboptimal and has not considerably improved over time despite the growth in our knowledge of the biology and unique characteristics of NETs. Higher quality is seen in randomised trials, although certain design and reporting elements remain inadequate in some studies. We must prioritise the design and conduct of NET clinical trials to effectively inform future research and guide practice change.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos Clínicos Fase III como Asunto / Ensayos Clínicos Fase II como Asunto / Tumores Neuroendocrinos / Reportes Públicos de Datos en Atención de Salud Tipo de estudio: Clinical_trials / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Neuroendocrinol Asunto de la revista: ENDOCRINOLOGIA / NEUROLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos Clínicos Fase III como Asunto / Ensayos Clínicos Fase II como Asunto / Tumores Neuroendocrinos / Reportes Públicos de Datos en Atención de Salud Tipo de estudio: Clinical_trials / Systematic_reviews Aspecto: Patient_preference Límite: Humans Idioma: En Revista: J Neuroendocrinol Asunto de la revista: ENDOCRINOLOGIA / NEUROLOGIA Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos